JACOB GOTTLIEB, MD, CFA, PRM
Jacob Gottlieb, MD, CFA, PRM is the Managing Partner and Chief Investment Officer of Altium Capital Management. Prior to founding Altium, Jake founded and led Visium Asset Management, which he grew from inception to over $8 billion in assets under management and over 175 employees in New York, San Francisco and London. Prior to Visium, Jake was a Portfolio Manager at Balyasny Asset Management and Sanford C. Bernstein (now Alliance Bernstein). Jake graduated magna cum laude from Brown University, then attended New York University Medical School earning his medical degree in 1997. He obtained his CFA charter in 2001, and his PRM designation from the Professional Risk Managers' International Association in 2010.
Joshua Thomas is a Portfolio Manager at Altium Capital Management. Joshua has over 14 years of hedge fund investing experience, including responsibility for risk management, idea generation, and the development of research processes and trading strategies.
Prior to Altium, Joshua was the Managing Partner of Midsummer Capital, the investment manager of several hedge funds operating in the small cap sector. He oversaw the launch and management of Midsummer Small Cap, an equity long/short product, from 2010 through its wind down in 2016. Also during his tenure at Midsummer, Joshua served on the board of directors of several portfolio companies, structured and negotiated complex securities, and led both operational and financial restructurings.
Joshua began his career in various roles in investment banking and equity analysis at Merrill Lynch, ABN Amro and Sanford Bernstein. During his time in investment banking, he marketed and executed a variety of transactions, including private placements, venture financings, and mergers and acquisitions. In equity research at Sanford Bernstein, Mr. Thomas covered broadline retailers and helped to launch coverage on the department store sector. Joshua holds a BA in Economics from Vanderbilt University (magna cum laude).
JOSEPH V. GULFO, MD, MBA
Joseph Gulfo has more than 25 years of experience in the biopharmaceutical and medical device industries. Joseph served as President, CEO, and Chairman of MELA Sciences until 2013. While at MELA Sciences, he was responsible for effecting an IPO and consummating 11 public financings totaling ~$160 MM and obtaining FDA approval of the MelaFind PMA despite an initial setback, through which he gained national attention. As President & COO of Anthra Pharmaceuticals and Chairman of its UK subsidiary, he was responsible for the 1998 NDA approval of Valstar. Dr. Gulfo was also instrumental in the development of ProstaScint (Cytogen Corporation), a BLA-approved monoclonal antibody for prostate cancer. He was CEO and Chairman of Antigen Express, an immunotherapy and immunodiagnostics company, and led its merger.
In 2012, Joseph received the American Business Awards’ Maverick of the Year Award and was an Ernst & Young Entrepreneur of the Year Finalist. He is the author of The Care Quotient: Transforming Business Through People (Post Hill Press, September 2016) and Innovation Breakdown: How the FDA and Wall Street Cripple Medical Advances (Post Hill Press, June 2014). He is also the author of several papers including The Proper Role of the FDA for the 21st Century (The Mercatus Center, 2016), How Can the FDA Foster Greater Resilience in the Medical Marketplace (Niskanen Center, 2018), and Product Approvability Recommendations from FDA Advisory Committees: Inconsistently Sought, Indirectly Obtained (Sage Journals, 2018). His work has been published in the Wall Street Journal, Forbes, CNBC, US News & World Report, and other national publications. He teaches graduate cancer biology at Seton Hall University.
DAVID LIU, PhD
David Liu joined Altium Capital Management in January 2019. Prior to joining Altium, David was a Senior Analyst at Iguana Healthcare Partners, a long/short equity hedge fund, where he focused on therapeutics. Previously, he was an Equity Research Associate at RBC Capital Markets focusing on US small and mid-cap biotech.
David received a Ph.D in Molecular Biology from Cornell University, and conducted his thesis research in oncology at the Memorial Sloan-Kettering Cancer Center. He graduated from Stanford University with a BS in Biological Sciences.
TIMOTHY RAMDEEN, MBA
Timothy Ramdeen joined Altium Capital Management in July 2019. Prior to Altium, Tim was an analyst at Brio Capital Management, an Event-Driven/Special Situations hedge fund focused on small-cap equities. At Brio, Tim invested as a generalist, but with a principal focus on the Healthcare sector (Therapeutics, Biotechnology, Medical Devices). He began his buy-side career on the M&A team at Focus Financial Partners, a specialized holding company, and also worked in private equity investing for a New York-based firm.
Tim holds a BS in Biology from Temple University and an MBA from NYU Stern School of Business.
Jim Tumbrink joined Altium Capital Management in August 2019. Jim was previously an Analyst at Broadfin Capital and Tavio Capital, two long/short healthcare dedicated funds. He began his career as an Equity Research Associate in Pharmaceuticals at BMO Capital Markets, with other sell-side positions at Citadel Securities and WJB Capital focused on Biotechnology. Jim graduated from Michigan State University with a BS in Microbiology and Molecular Genetics.
Jacob O’Donnell joined Altium Capital Management in June 2020. Prior to Altium, Jacob was a Trader at Kettle Hill Capital Management, a fundamental long/short equity hedge fund focused on small and mid-cap equities. Prior to Kettle Hill, Jacob was responsible for all aspects of trading and operations at ShearLink Capital, a fundamental long/short equity hedge fund. Jacob graduated from Drew University in Madison, New Jersey with a BA in Economics. Additionally, Jacob holds a MS in Finance from the University of Rochester’s Simon Business School.
ERIC CHENG, MBA
Eric Cheng joined Altium Capital in August 2020 and is a Managing Director at Altium Capital Management where he is focused on investments in private capital markets and special situations. Eric has over 26 years of finance and accounting experience, including 23-years as an investment banker primarily focused on the life sciences sector during which he completed approximately 200 equity, debt and M&A transactions, representing over $13 billion in aggregate value.
Prior to Altium, Eric was Managing Director and Co-Head of Healthcare Investment Banking at Roth Capital Partners where he led the successful rebuilding of the firm’s life sciences business. Prior to Roth, Eric was Senior Managing Director and Head of Healthcare Investment Banking at Maxim Group. Prior to joining Maxim, Eric was a senior life sciences banker at BMO Capital Markets and WR Hambrecht & Co. He has also been an investment banker with Deutsche Bank Securities and Lehman Brothers. Eric began his career as a public accountant at Deloitte & Touche. Eric holds a BA from the University of California at Los Angeles and an MBA from Columbia Business School.
VICTOR GEZUNTERMAN, MBA
Victor Gezunterman is a Portfolio Manager at Altium, a role he has held since October 2020. Mr. Gezunterman has over 16 years of experience investing in, researching, and analyzing healthcare companies. Prior to joining Altium, he was responsible for medical technology investing at Broadfin Capital, a healthcare-focused investment firm, as a Senior Analyst from 2017 to 2020. He started his buy-side career at SAC Capital’s Sigma division in 2010, serving as a Senior Analyst until 2013. Prior to joining the buy-side, Mr. Gezunterman worked in sell-side equity research at Morgan Stanley from 2006 to 2009 and Thomas Weisel Partners (now Stifel) from 2003 to 2006, where he covered medical technology and diagnostic companies. Mr. Gezunterman started his career at Boston Biomedical Consultants, a management consulting firm, in 1997. Mr. Gezunterman earned his B.A. in Economics from Brandeis University and his M.B.A. from the University of Chicago.
Alex Pelekhaty joined Altium Capital Management in September 2020. Prior to Altium, Alex was an Analyst at Jefferies & Company as part of a long/short equity principal investments desk focusing on special situations/fundamental investments across TMT and other sectors. Previously, he was a long/short equity TMT analyst at Weiss Multi-Strategy Advisers. He began his career as a generalist investment banking analyst at Moelis & Company focusing on M&A and Restructuring advisory across various sectors. Alex graduated from New York University Stern School of Business with a BS in Finance and Accounting.
DYLAN DUPUIS, PhD
Dylan Dupuis joined Altium Capital in March 2021. Most recently, Dylan was a Vice President, Equity Research at SVB Leerink where he covered small and mid-cap companies with a focus on Inflammation and Immunology (I&I) therapeutics. Prior to SVB Leerink, Dylan was a Research Associate at B. Riley FBR covering small and mid-cap biotechnology companies, and previously worked as a Trader at Seven Points Capital. Dylan received a PhD in Molecular Biology from Lehigh University and completed his post-doctoral research at the Center for Vascular Biology Research at Beth Israel Deaconess Medical Center in Boston, MA. He graduated from Lycoming College with a BS in Biology and Chemistry.
ARAVINDA KUNTIMADDI, PhD
Aravinda Kuntimaddi joined Altium Capital in April 2021. Previously, he spent three years at SVB Leerink as an Equity Research Associate where he primarily was on a team covering small and mid-cap companies in the Genetic Medicine sector. Prior to entering Wall Street, he spent a year as a Medical Director at Harrison & Star after completing his Postdoctoral Research at Genentech. Aravinda received his PhD in Biophysics from the University of Virginia and graduated from Northwestern University where he holds undergraduate degrees in Biological Sciences and Psychology.
Rohan Ranadive joined Altium Capital Management in September 2020. Prior to Altium Capital, Rohan was a Senior Analyst at Back Bay Life Science Advisors, a Boston-based boutique investment bank, where he advised on M&A transactions in the biopharmaceutical and medtech sectors. He completed his MS in Biotechnology from Georgetown University and holds a BS in Neuroscience from Northeastern University.
Lauren Kelley joined Altium Capital in September 2020 to manage talent acquisition for the firm. Prior to Altium Capital, Lauren was a Business Development Associate at Point72 Asset Management focused on hiring analysts and portfolio managers for their long/short equity platform. Lauren graduated from Southern Methodist University with a BBA in Management
ANDREW LOGGIA, CPA
Prior to joining Altium, Andrew was the Chief Financial Officer of Trafelet & Company, a fundamental long/short equity hedge fund focused on small and mid-cap equities. Prior to Trafelet, Andrew was a Managing Director at Ramius LLC, the global alternative investment management business of Cowen Group, Inc., where he was head of accounting and reporting for the entire hedge fund business. He spent 12 years at Ramius where he assisted in building out the accounting/operational infrastructure, including designing controls and accounting process in accordance with best practices. He began his career as an auditor at Deloitte Touche Tohmatsu Limited, where he performed annual audits on a variety of investment companies. He earned a BBA in public accounting from Pace University, Manhattan campus. He is a New York State Certified Public Accountant.
MARK GOTTLIEB, CFA, CAIA, MBA
Prior to Altium, Mark was Partner & Chief Administrative Officer of Visium Asset Management, a New York-based hedge fund manager which evolved into a global multi-strategy hedge fund, private equity, and mutual fund company at its peak, with over 175 staff among NY, San Francisco and London offices. He led development of the firm from inception (successful spin-out of Visium from Balyasny Asset Management), including operations and accounting infrastructure, corporate development, recruiting, and various expansion efforts.
Prior to Visium, Mark was on the investment team at Balyasny, primarily focused on negotiating private investments in public companies in development-stage healthcare (biotech, pharmaceuticals, devices). Mark started his career in corporate finance investment banking at UBS.
Mark holds a MBA from Cornell University in Entrepreneurship & Venture Capital and a BA from Vassar College in Economics. He is a CFA charterholder, and a CAIA charterholder.